為什麽現在投資 SAVA

Quote from Yahoo Finance (Comments by Alex):

"Here are two things that I have zero doubt that are taking place regardless of phase 2b publication status (though this works as well，as long as they comply with CTAD policy regarding publication):
1. On-going partnering discussions....to me it’s a no brainer, I know how the industry works, they are talking to sava now，no doubt given the immense data-set they have assembled.
2. FDA breakthrough designation application....again this is a no brainer, no need to wait for publication, they present the totality of their data set in an application to fda，and then wait for 60 days for response from fda. They can do the application without PR. However once they receive acceptance of BTD.....sava will issue a PR. Then it will be game over for shorts and see you at min 50 pps.

I am buying more based on my confidence of the above 2 points. Every one should make their own assessment but when either of these two news hits.....game over! No one can buy in at current value after that....."

BIIB的新藥Aducanumab被專家組否定，對SAVA其實是利好消息，這大大增加了SAVA和大公司合作或被收購的可能性。接下來一段時間內的SAVA股價，估計會上下抖動得厲害。再去一次以前的低點也不是不可能。這是莊家在拉升之前的慣用技巧。所謂shake the tree to collect the shares。我們要做的，就是逢低買入，然後拿住不動---因為無法預測哪天Cassava公司會放出這種爆炸性的消息，所以最好別低買高賣。

從AVXL今天的表現來看，加上之前查到的一些關於Anavax的負麵新聞，我還是堅持之前的觀點，對AVXL不看好，也不準備持有。這個股票很可能最後落個pump & dump的結局：https://bbs.wenxuecity.com/finance/5236662.html 

純個人觀點，不做投資建議。YMYD